Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Glycomimetics Inc (GLYC)

Glycomimetics Inc (GLYC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,083
  • Shares Outstanding, K 64,484
  • Annual Sales, $ 10 K
  • Annual Income, $ -36,900 K
  • EBIT $ -42 M
  • EBITDA $ -42 M
  • 60-Month Beta 1.77
  • Price/Sales 1,508.28
  • Price/Cash Flow N/A
  • Price/Book 1.33
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.46
  • Most Recent Earnings $-0.15 on 11/13/24
  • Next Earnings Date 11/15/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 342.84% ( -34.65%)
  • Historical Volatility 98.63%
  • IV Percentile 64%
  • IV Rank 25.44%
  • IV High 1,196.80% on 07/09/24
  • IV Low 51.53% on 07/17/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 252
  • Volume Avg (30-Day) 96
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 2,730
  • Open Int (30-Day) 7,441

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1912 +13.23%
on 12/19/24
0.3662 -40.88%
on 12/02/24
-0.1003 (-31.66%)
since 11/22/24
3-Month
0.1406 +53.98%
on 10/09/24
0.6300 -65.63%
on 10/29/24
+0.0520 (+31.61%)
since 09/23/24
52-Week
0.1406 +53.98%
on 10/09/24
3.5299 -93.87%
on 01/23/24
-2.3235 (-91.48%)
since 12/22/23

Most Recent Stories

More News
GlycoMimetics: Q3 Earnings Snapshot

GlycoMimetics: Q3 Earnings Snapshot

GLYC : 0.2165 (-7.44%)
GlycoMimetics: Q1 Earnings Snapshot

GlycoMimetics: Q1 Earnings Snapshot

GLYC : 0.2165 (-7.44%)
GlycoMimetics: Q4 Earnings Snapshot

GlycoMimetics: Q4 Earnings Snapshot

GLYC : 0.2165 (-7.44%)
GlycoMimetics: Q3 Earnings Snapshot

GlycoMimetics: Q3 Earnings Snapshot

GLYC : 0.2165 (-7.44%)
GlycoMimetics: Q2 Earnings Snapshot

GlycoMimetics: Q2 Earnings Snapshot

GLYC : 0.2165 (-7.44%)
GlycoMimetics: Q1 Earnings Snapshot

GlycoMimetics: Q1 Earnings Snapshot

GLYC : 0.2165 (-7.44%)
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023

GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial...

GLYC : 0.2165 (-7.44%)
GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2023 financial results on Wednesday, May 3, 2023, at 8:30 a.m. ET.

GLYC : 0.2165 (-7.44%)
GlycoMimetics: Q4 Earnings Snapshot

GlycoMimetics: Q4 Earnings Snapshot

GLYC : 0.2165 (-7.44%)
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022

GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial...

GLYC : 0.2165 (-7.44%)

Business Summary

GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at...

See More

Key Turning Points

3rd Resistance Point 0.2581
2nd Resistance Point 0.2486
1st Resistance Point 0.2325
Last Price 0.2165
1st Support Level 0.2069
2nd Support Level 0.1974
3rd Support Level 0.1813

See More

52-Week High 3.5299
Fibonacci 61.8% 2.2352
Fibonacci 50% 1.8353
Fibonacci 38.2% 1.4353
Last Price 0.2165
52-Week Low 0.1406

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar